Rx
🏭 GSK
❄️ Cold Chain
🛡️ Groups A·C·Y·W-135
🕌 Hajj / Umrah
Menveo® · GSK · 0.5 mL after Reconstitution · Intramuscular Injection
4 Serogroups A, C, Y, W-135 · CRM197 Conjugate · GSK India
🛡️ 4 Meningococcal Serogroups Menveo Protects Against
A
Serogroup A
Dominant in Sub-Saharan Africa's "Meningitis Belt." Also prevalent in Asia and cause of Hajj-associated outbreaks. Each dose: 10 mcg oligosaccharide (CRM197 conjugate)
C
Serogroup C
Major cause of meningitis in Europe and Americas. Common in adolescent outbreaks and college dormitory clusters. Each dose: 5 mcg oligosaccharide (CRM197 conjugate)
Y
Serogroup Y
Increasingly common in the USA and parts of Europe. Causes pneumonia as well as meningitis. Each dose: 5 mcg oligosaccharide (CRM197 conjugate)
W
Serogroup W-135
Historically linked to Hajj pilgrimage outbreaks. Also rising globally with invasive disease. Each dose: 5 mcg oligosaccharide (CRM197 conjugate)
ℹ️ What is Bacterial Meningitis? Neisseria meningitidis causes inflammation of the membranes surrounding the brain and spinal cord. It can progress from first symptoms to death in under 24 hours. Survivors may face permanent hearing loss, brain damage or limb amputation. Menveo provides robust conjugate-based protection against all four of the most prevalent serogroups.
👥 Who Should Get Menveo (MCV4)?
Children (9 Months – 10 Years)
Children at increased risk (travel, asplenia, complement deficiency) from age 9 months. 2-dose primary series. All children: single dose from 2 years.
Adolescents (11–18 Years)
IAP recommends at 11–12 years with a booster at 16 years. College students, military recruits and students entering dormitories are at elevated risk.
Hajj & Umrah Pilgrims ⭐
Saudi Arabia mandates ACYW-135 meningococcal vaccination. Menveo satisfies this requirement. Recommended ≥10 days before travel for best protection.
International Travellers
Travel to Sub-Saharan Africa ("Meningitis Belt"), Southeast Asia, or any active meningococcal outbreak area. Essential pre-travel vaccination.
High-Risk Medical Conditions
Asplenia (no spleen), complement deficiency (C5–C9, properdin, factor D/H), HIV infection. These conditions dramatically increase risk of invasive meningococcal disease.
Microbiologists & Lab Workers
Occupational exposure to Neisseria meningitidis in research or diagnostic settings. Vaccination is an occupational health requirement in many institutions.
🔬 Menveo Composition – Per 0.5 mL Single Dose
As per GSK manufacturer label. Each 0.5 mL vial contains:
| Component | Quantity | Notes |
|---|---|---|
| ACTIVE INGREDIENTS – MENINGOCOCCAL POLYSACCHARIDES | ||
| Meningococcal Serogroup A Polysaccharide | 10 mcg | Individually conjugated to CRM197 protein |
| Meningococcal Serogroup C Polysaccharide | 5 mcg | Individually conjugated to CRM197 protein |
| Meningococcal Serogroup Y Polysaccharide | 5 mcg | Individually conjugated to CRM197 protein |
| Meningococcal Serogroup W-135 Polysaccharide | 5 mcg | Individually conjugated to CRM197 protein |
| CARRIER PROTEIN | ||
| CRM197 Protein | 48 mcg | Carrier protein — each polysaccharide individually conjugated |
| EXCIPIENTS | ||
| Sodium chloride | 4.35 mg | Tonicity agent |
| Sodium phosphate | 0.7 mg | Buffer |
| Water for injection | Up to 0.5 mL | Vehicle |
💡 Why Conjugate? Older polysaccharide meningococcal vaccines (e.g. Mencevax) stimulate a T-cell-independent response and provide no lasting immunity in children under 2 and waning immunity in adults. Menveo's conjugate technology links each polysaccharide to CRM197 Protein, creating a T-cell-dependent response — generating immunological memory, longer-lasting protection and a stronger booster effect on re-exposure.
📅 Menveo – IAP 2024 Vaccination Schedule
| Group | Dose | Age / Timing | Notes |
|---|---|---|---|
| High-risk infants | 2 Doses | 9 months + 12 months | Asplenia, complement deficiency, travel |
| Children 2–10 years | 1 Dose | From 2 years | Single dose; booster in 3–5 years if still at risk |
| Adolescents (routine) | 2 Doses | 11–12 years + booster at 16 years | IAP recommended schedule |
| Adults (standard) | 1 Dose | Any time (if not vaccinated) | Booster every 5 years if at continued risk |
| Hajj / Umrah pilgrims | 1 Dose | ≥10 days before travel | Saudi Arabia requirement for ACYW-135; certificate needed |
| International travel | 1 Dose | ≥2 weeks before travel | Sub-Saharan Africa, high-risk areas |
⚠️ Hajj Pilgrims: Vaccination must generally be administered at least 10 days before departure for adequate antibody levels to develop. Saudi Arabia requires proof of meningococcal vaccination for visa processing. Plan ahead — book with VacciHub well in advance of your travel date.
⚙️ How Does Menveo Work?
1
Polysaccharide-Protein Conjugates Injected
Each of the four meningococcal capsular polysaccharides (A, C, Y, W-135) is individually conjugated to CRM197 (a diphtheria toxoid derivative) Protein carrier (48 mcg). The 0.5 mL solution is injected intramuscularly (deltoid in adults; anterolateral thigh in young children).
2
T-Cell Activation (Conjugate Advantage)
The carrier protein recruits T-helper cells (CD4+), converting the immune response from T-independent to T-dependent. This is the key advantage of conjugate vaccines — without T-cell help, polysaccharide vaccines generate no immunological memory.
3
Serogroup-Specific Bactericidal Antibodies
The immune system generates high-titre IgG antibodies against the capsular polysaccharide of each serogroup (A, C, Y, W-135). These antibodies activate complement and opsonophagocytosis, killing N. meningitidis bacteria on contact.
4
Memory + Long-Term Protection
Memory B-cells specific to each serogroup are generated, enabling rapid anamnestic response on future exposure. Protection develops within 7–10 days of vaccination and lasts approximately 5 years in most individuals (longer in adolescents vaccinated in the primary series).
⚠️ Menveo Side Effects
Menveo has a well-established safety profile. It has been given to millions of adolescents and adults globally since its approval.
🟡 Common (Mild, Self-Limiting)
- 💉 Injection-site pain (very common)
- 🔴 Redness / induration at site
- 🤕 Headache
- 😴 Fatigue / malaise
- 🌡️ Low-grade fever, chills
🔴 Rare – Seek Medical Attention
- ⚡ Guillain-Barré Syndrome (GBS) – very rare
- 😵 Syncope (fainting) post-injection
- 🤒 High fever (>39°C)
- 🚨 Anaphylaxis (extremely rare)
💡 GBS Note: A very small number of GBS cases have been reported in temporal association with Menveo. The absolute risk is extremely low and the benefit of meningococcal vaccination vastly outweighs this risk, particularly for high-risk groups and travellers. Always observe for 15–30 minutes post-vaccination.
⚖️ Menveo (GSK) vs Menactra (Sanofi) – Comparison
Both are quadrivalent meningococcal conjugate vaccines protecting against serogroups A, C, Y and W-135. Key differences:
| Feature | Menveo (MCV4) | Menactra (MCV4) |
|---|---|---|
| Manufacturer | ✓ GSK | Sanofi Pasteur |
| Serogroups Covered | ✓ A, C, Y, W-135 | ✓ A, C, Y, W-135 |
| Carrier Protein | CRM197 (diphtheria toxoid derivative) | Diphtheria Toxoid |
| Minimum Age | ✓ 2 months (infants) | 9 months (high-risk) |
| Form | Lyophilised, requires reconstitution (2-vial pack) | ✓ Ready-to-use solution vial |
| Hajj Approved | ✓ Yes | ✓ Yes |
| Conjugate Technology | Each serogroup individually conjugated to CRM197 | Each serogroup individually conjugated to diphtheria toxoid |
| Available at VacciHub | ✓ Yes – home vaccination | On request |
🚫 Precautions & Contraindications
Do NOT give Menveo if:
- Known hypersensitivity to any vaccine component including CRM197 (diphtheria toxoid derivative)
- Severe allergic reaction to a previous meningococcal vaccine dose
- Acute moderate-to-severe febrile illness on vaccination day — defer
Use with Caution:
- History of Guillain-Barré Syndrome (GBS) — discuss risk-benefit with doctor
- Pregnancy — limited data; discuss with your obstetrician; benefit generally outweighs risk for high-risk situations
- Immunosuppressive therapy — may reduce immune response
- Thrombocytopenia or bleeding disorders — injection-site bleeding risk
✅ Hajj / Travel timing: For maximum protection, Menveo should be administered at least 10 days before potential meningococcal exposure (travel departure, Hajj season start). Earlier is always better — antibodies reach protective levels by day 7–10.
🏥 Why Book Menveo with VacciHub?
Certified Nursing Staff
Trained, certified nurses experienced in adult and travel vaccination. Proper IM technique guaranteed. Post-vaccination monitoring followed.
Cold Chain Guaranteed
Menveo transported in calibrated cold boxes at 2°C–8°C throughout. Never frozen. Potency guaranteed from warehouse to your home.
100% Genuine GSK
Sourced from authorised GSK distributors. Batch numbers traceable. No counterfeit risk.
Hajj Vaccination at Home
Get your mandatory Hajj/Umrah meningococcal certificate without visiting a clinic. VacciHub can assist with documentation guidance.
Travel Vaccination Specialists
Pre-travel vaccination consultation included. We help you identify all vaccines recommended for your destination alongside Menveo.
Same-Day & Weekend Slots
Urgent pre-travel vaccination? We offer same-day bookings across Delhi NCR, including Saturdays and Sundays.
📍 Menveo Home Vaccination – Cities We Serve
🏛️Delhi (All Areas)
🏙️Gurgaon
🌆Noida
🏘️Ghaziabad
🏗️Faridabad
🌇Greater Noida
Call +91 92050 04114 to confirm coverage of your pincode — same-day slots available.
❓ Frequently Asked Questions – Menveo Vaccine
Menveo (MCV4) is a quadrivalent meningococcal conjugate vaccine by GSK. It protects against Neisseria meningitidis serogroups A, C, Y and W-135 — the four strains responsible for the majority of fatal bacterial meningitis and meningococcal septicaemia cases worldwide. Each polysaccharide is conjugated to CRM197 (a diphtheria toxoid derivative) Protein for long-lasting immunological memory.
Yes. Saudi Arabia mandates proof of ACYW-135 meningococcal vaccination for all Hajj and Umrah pilgrims. Menveo (MCV4) covers all four required serogroups (A, C, Y, W-135) and fully satisfies this requirement. Vaccination should be done at least 10 days before departure. VacciHub provides home vaccination for Hajj pilgrims across Delhi NCR — call +91 92050 04114.
Menveo can be given from 9 months of age in high-risk children (asplenia, complement deficiency, travel). For routine vaccination, it is given from 2 years as a single dose. Adolescent routine vaccination is recommended at 11–12 years with a booster at 16 years as per IAP 2024 guidelines.
Older vaccines like Mencevax (polysaccharide) generate a T-cell-independent immune response — no memory cells are created, protection lasts only 3–5 years and they are ineffective in children under 2. Menveo is a conjugate vaccine — each polysaccharide is linked to CRM197 Protein, recruiting T-helper cells and generating immunological memory. This means longer-lasting protection, an effective booster response, and protection from 9 months of age.
For most adults and adolescents with ongoing risk, a booster every 5 years is recommended. For the adolescent routine schedule: dose at 11–12 years + booster at 16 years. For Hajj/Umrah pilgrims: one dose per travel season where required. Persons with asplenia or complement deficiency may need boosters every 3–5 years.
Absolutely. VacciHub provides home vaccination with genuine GSK Menveo across Delhi, Gurgaon, Noida, Ghaziabad, Faridabad and Greater Noida. This is especially convenient for families preparing for Hajj/Umrah or pre-travel vaccination. Same-day bookings available. Call +91 92050 04114.
Common side effects are mild: injection-site pain, redness, headache, fatigue, low-grade fever — all resolving within 1–3 days. A very rare association with Guillain-Barré Syndrome (GBS) has been reported but the absolute risk is extremely small and the benefit of vaccination far outweighs it, especially for travellers and high-risk individuals. Observe the patient for 15–30 minutes post-injection — our nurses follow this protocol.